Abstract:ABSTRACT Genetically-engineered immune cell therapies have been in development for decades 1–3 and recently have proven effective to treat some types of cancer 4 . CRISPR-based genome editing methods, enabling more flexible and targeted sequence integrations than viral transduction, have the potential to extend the clinical utility of cell therapies 5,6 . Realization of this potential depends on improved knowledge of how coding and non-coding sites throughout the genome can be modified efficiently and on improved methods to discover novel synthetic DNA sequences that can be introduced at targeted sites to enhance critical immune cell functions. Here, we developed improved guidelines for non-viral genome targeting in human T cells and a pooled discovery platform to identify synthetic genome modifications that enhance therapeutically-relevant cell functions. We demonstrated the breadth of targetable genomic loci by performing large knock-ins at 91 different genomic sites in primary human T cells, and established the power of flexible genome targeting by generating cells with Genetically Engineered Endogenous Proteins (GEEPs) that seamlessly integrate synthetic and endogenous genetic elements to alter signaling input, output, or regulatory control of genes encoding key immune receptors. Motivated by success in introducing synthetic circuits into endogenous sites, we then developed a platform to facilitate discovery of novel multi-gene sequences that reprogram both T cell specificity and function. We knocked in barcoded pools of large DNA sequences encoding polycistronic gene programs. High-throughput pooled screening of targeted knock-ins to the endogenous T cell receptor (TCR) locus revealed a transcriptional regulator and novel protein chimeras that combined with a new TCR specificity to enhance T cell responses in the presence of suppressive conditions in vitro and in vivo . Overall, these pre-clinical studies provide flexible tools to discover complex synthetic gene programs that can be written into targeted genome sites to generate more effective therapeutic cells.

Highly Efficient Homology-Driven Genome Editing in Human T Cells by Combining Zinc-Finger Nuclease Mrna and AAV6 Donor Delivery.

Homology-driven Genome Editing in Hematopoietic Stem and Progenitor Cells Using ZFN Mrna and AAV6 Donors

Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells.

Cas9-cleavage sequences in minimal plasmids enhance non-viral genome targeting of CARs in primary human T cells

An evolved AAV variant enables efficient genetic engineering of murine T cells

Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases.

In vivo human T cell engineering with enveloped delivery vehicles

Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Identification of core techniques that enhance genome editing of human T cells expressing synthetic antigen receptors

Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells

Precision genome editing using combinatorial viral vector delivery of CRISPR-Cas9 nucleases and donor DNA constructs

High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing

Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells

Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells

CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Highly Efficient Genome Editing of Human Hematopoietic Stem Cells Via a Nano-Silicon-blade Delivery Approach.

Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery

Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours